Fig. 2From: Relevance of immune cell and tumor microenvironment imaging in the new era of immunotherapy99mTc-IL2 SPECT-CT in patients affected by metastatic melanoma before (top) and after (bottom) immunotherapy with ipilimumab. a) Patient with a 99mTc-IL2-positive lesion that responded to therapy. b) Multimetastatic patient with different degree of uptake of 99mTc-IL2Back to article page